EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.

View source ↗

Summary

Kyprolis (carfilzomib) has been authorised by the EMA for multiple myeloma, with accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Amgen Europe B.V.. Decision date: 25/06/2026. Accelerated assessment